Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Dowpharma, Abbott Enter Technology Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Dowpharma, Abbott Enter Technology Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abbott has entered into a commercial license agreement with Dowpharma for its Pfenex Expression Technology, a Pseudomonas-based technology for biologic production. Abbott’s product is a proprietary protein for which the company has already developed a high-yield production strain and a fully scalable process. Dow will transfer the production strain to Abbott and support its regulatory filing. Under the agreement, Abbott will have a non-exclusive license to use Pfenex for the development and manufacture of the drug.

“This agreement with Abbott is yet another validation in a long line of agreements by the pharmaceutical industry that our technologies continue to deliver valued solutions. We are pleased to be working with Abbott to help fulfill its future protein production needs as part of this commercial license agreement,” said Nick Hyde, global business director for Dowpharma. “Proteins produced by Pfenex Expression Technology are now in human clinical trials and the system consistently delivers high quality protein faster than traditional expression systems.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics